Nitto Avecia’s Milford Facility Receives FDA No Action Indicated Classification Following cGMP Inspection
Nitto Avecia, a contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics, announced that the U.S. Food and Drug Administration (FDA) has classified its recently completed inspection of the company’s Milford, Massachusetts facility as No Action Indicated (NAI).
The favorable regulatory outcome followed an unannounced six-day routine current Good Manufacturing Practice (cGMP) inspection conducted by the FDA at the Milford site. The inspection concluded with zero FDA Form 483 observations, indicating that the agency did not identify conditions or practices that warranted the issuance of formal inspectional observations.
The latest result represents an important quality and regulatory milestone for Nitto Avecia and extends a consistent record across the company’s U.S. manufacturing network. The Milford facility is now the third consecutive Nitto Avecia site in the United States to complete an FDA inspection with both zero Form 483 observations and an NAI classification.
Nitto Avecia’s Cincinnati, Ohio facility achieved the same outcome in 2024, followed by the company’s Irvine, California facility in 2025. With the Milford facility receiving an NAI classification in 2026, all three facilities have now achieved favorable outcomes in their respective most recent FDA inspections.
According to Nitto Avecia, the series of inspection results demonstrates the consistency of its quality systems across its U.S. operations and reinforces the company’s focus on maintaining high standards for manufacturing quality and regulatory compliance.
Milford FDA Inspection Ends Without Form 483 Observations
The FDA’s six-day inspection of Nitto Avecia’s Milford facility was conducted as an unannounced routine cGMP inspection. Such inspections are designed to assess whether pharmaceutical manufacturing operations are operating in compliance with applicable regulatory requirements and whether appropriate systems are in place to maintain product quality, safety and consistency.
The Milford inspection resulted in no FDA Form 483 observations. An FDA Form 483 is generally issued when investigators identify conditions that, in their judgment, may constitute violations of applicable regulatory requirements. The absence of observations therefore represents a favorable inspection outcome for the facility.
Following the inspection, the FDA classified the site as No Action Indicated. An NAI classification indicates that, based on the inspection findings, the agency did not identify conditions requiring regulatory action.
For a CDMO supporting pharmaceutical and biotechnology companies, such regulatory outcomes can be particularly important because manufacturing partners play a critical role in the development, production and supply of drug substances and other pharmaceutical materials. Customers depend on CDMOs to maintain robust quality systems and comply with applicable manufacturing standards as their products progress through development and commercialization.
Nitto Avecia said the latest inspection outcome reinforces its ability to provide manufacturing services under a consistent quality framework.
Third Consecutive NAI Result Across U.S. Facilities
The Milford inspection result is notable because it follows two consecutive favorable FDA inspections at other Nitto Avecia facilities.
The company’s Cincinnati, Ohio facility completed its most recent FDA inspection in 2024 with zero Form 483 observations and an NAI classification. In 2025, Nitto Avecia’s Irvine, California facility achieved the same outcome. The company’s Milford facility has now extended that record into 2026.
Together, the three results provide evidence of consistency in the company’s approach to quality management across its U.S. operations.
Rather than representing an isolated outcome at a single manufacturing location, the consecutive results across Cincinnati, Irvine and Milford demonstrate that Nitto Avecia’s quality systems are being maintained across multiple facilities.
For customers developing oligonucleotide therapeutics, consistency across manufacturing locations can be an important consideration. Pharmaceutical and biotechnology companies must ensure that their manufacturing partners can operate under stringent quality requirements while supporting complex development and production programs.
The latest inspection outcome provides Nitto Avecia with another regulatory milestone that can reinforce confidence among existing and prospective customers seeking CDMO services for oligonucleotide-based medicines.
FDA’s Six-System Inspection Framework
The FDA’s cGMP inspections of pharmaceutical manufacturing operations evaluate a range of systems that collectively provide insight into the overall state of control at a facility.
Nitto Avecia noted that FDA cGMP inspections of the Pharmaceutical Quality System (PQS) use a six-system model. The framework encompasses Quality, Facilities and Equipment, Materials, Production, Packaging and Labeling, and Laboratory Controls.
These six systems provide a structured framework for assessing whether pharmaceutical manufacturing operations are appropriately controlled and whether the systems supporting production and quality are functioning effectively.
A full inspection under the FDA framework would cover at least four of the six systems, with the Quality System required to be one of the systems examined.
The inspection model enables regulators to evaluate different aspects of a pharmaceutical manufacturing operation, from the overarching quality framework and facility infrastructure to materials management, manufacturing processes, packaging and laboratory activities.
For CDMOs, maintaining effective controls across these areas is essential. Manufacturing organizations must establish processes that consistently meet cGMP requirements while ensuring that products and materials are manufactured according to appropriate specifications and quality standards.
The NAI classification following the Milford inspection therefore provides a favorable assessment of the facility’s performance under the FDA’s regulatory framework.
Quality Systems Central to Oligonucleotide Manufacturing
Nitto Avecia specializes in the development and manufacturing of oligonucleotide therapeutics, a growing area of pharmaceutical innovation. Oligonucleotide-based medicines include therapeutic modalities designed to interact with genetic or molecular pathways, creating opportunities for the development of treatments across a range of diseases.
The manufacturing of oligonucleotide therapeutics involves specialized processes and requires appropriate controls throughout development and production. As pharmaceutical companies advance oligonucleotide programs toward clinical development and commercialization, CDMOs can provide critical capabilities and manufacturing infrastructure.
For these customers, regulatory compliance and quality performance are fundamental components of a CDMO relationship.
Nitto Avecia said its quality systems are designed to support biotechnology and pharmaceutical partners as they develop innovative therapies. The company’s latest FDA inspection outcome underscores its emphasis on maintaining those systems across its U.S. facilities.
“At Nitto Avecia, we strive every day to meet and exceed rigorous quality standards and client expectations, enabling our biotechnology and pharmaceutical partners to confidently rely on the quality of the active pharmaceutical ingredients we manufacture as they advance innovative therapies,” said Tammy Cooper, President at Nitto Avecia.
Cooper added that the company is proud that its three facilities have now completed their most recent FDA inspections with NAI classifications.
“We are exceptionally proud that all three facilities have now completed their most recent FDA inspections with an NAI classification,” Cooper said. “Achieving this outcome across multiple sites demonstrates the strength and consistency of our quality systems and, most importantly, reflects the dedication, expertise, and commitment demonstrated every day by our employees across Quality, Development, and Operations.”
Supporting Pharmaceutical and Biotechnology Customers
The favorable inspection result also highlights the role of CDMOs in supporting the broader pharmaceutical development ecosystem.
Drug developers increasingly rely on specialized manufacturing organizations for development, process support and production capabilities. For companies developing complex therapies, selecting a manufacturing partner with appropriate technical expertise and a strong regulatory record can be an important part of advancing a program.
Nitto Avecia’s focus on oligonucleotide therapeutics positions the organization within a specialized segment of the CDMO industry. Its U.S. facilities provide manufacturing infrastructure intended to support pharmaceutical and biotechnology customers developing oligonucleotide-based therapies.
The company’s consecutive FDA inspection results may help reinforce its position as a manufacturing partner for customers that prioritize regulatory compliance and quality performance.
The Milford facility’s latest inspection also demonstrates the importance of maintaining quality systems continuously rather than treating regulatory inspections as isolated events. FDA inspections evaluate the systems and controls that govern manufacturing operations, making day-to-day employee practices and organizational quality culture important components of sustained compliance.
According to Nitto Avecia, the latest result reflects the contributions of employees working across Quality, Development and Operations.
Continued Commitment to Regulatory Compliance
The 2026 Milford inspection outcome adds to Nitto Avecia’s recent record of successful FDA inspections and provides another indication of the company’s commitment to maintaining regulatory compliance across its U.S. network.
With Cincinnati achieving an NAI classification in 2024, Irvine following in 2025 and Milford completing the sequence in 2026, the company has established three consecutive favorable FDA inspection outcomes across its facilities.
The absence of Form 483 observations at all three sites is particularly significant because it indicates that FDA investigators did not identify conditions during those inspections that warranted formal observations.
For Nitto Avecia, the results offer an opportunity to demonstrate the consistency of its quality approach to current and prospective customers. For pharmaceutical and biotechnology companies, the regulatory standing of a manufacturing partner can be an important element of supply-chain planning and development strategy.
The latest milestone also comes as interest in oligonucleotide therapeutics continues to drive demand for specialized development and manufacturing capabilities. As more biotechnology and pharmaceutical companies advance oligonucleotide candidates through clinical and commercial stages, CDMOs with specialized expertise and established quality systems can play an increasingly important role in supporting those programs.
Overall, Nitto Avecia’s Milford facility’s NAI classification following the FDA’s six-day unannounced cGMP inspection marks another favorable regulatory milestone for the company. The inspection concluded with zero Form 483 observations, extending a three-year sequence of similarly positive FDA outcomes across Nitto Avecia’s U.S. facilities.
The company said the results demonstrate the strength and consistency of its quality systems while recognizing the contribution of its employees across Quality, Development and Operations. As Nitto Avecia continues supporting pharmaceutical and biotechnology customers developing oligonucleotide therapeutics, the latest FDA outcome further underscores its stated commitment to quality, regulatory compliance and reliable manufacturing operations.
About Nitto Avecia
Nitto Avecia , a Nitto Denko Group company, is a leading oligonucleotide CDMO delivering development and manufacturing solutions from preclinical development through commercial supply. Nitto Avecia offers expertise in analytical development, process development, cGMP drug substance manufacturing, process performance qualification (PPQ) and quality control, supporting oligonucleotide modalities and chemistries.
Nitto Avecia partners with biotechnology and pharmaceutical companies to accelerate the development and commercialization of innovative nucleic acid therapeutics. For more information, visit www.avecia.com .